Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-κB activation of lipopolysaccharide-stimulated macrophages

Cytokine

Volumn 21, Issue 1, 2003, Pages 38-42

  Sano, Chiaki ^a   Shimizu, Toshiaki ^a   Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Lipopolysaccharide; Macrophages; Nuclear factor B; Secretory leukocyte protease inhibitor; Tumor necrosis factor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DIMER; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; GENE MUTATION; GENE OVEREXPRESSION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0037422706     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-4666(02)00485-4     Document Type: Article

References (22)

1. Smith C.F., Johnson A. Human bronchial leukocyte protease inhibitor. Biochem J. 225:1985;463-472.
2. Thompson R.C., Ohlsson K. Isolation, properties, and complete amino acid sequence of human leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 83:1986;6692-6696.
3. Jin F., Nathan C., Radzioch D., Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 88:1997;417-426.
4. Jin F., Nathan C.F., Radzioch D., Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 66:1998;2447-2452.
5. Watson J., Kelly K., Largen M., Taylor B.A. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol. 120:1978;422-424.
6. 2, and matrix metalloproteinases. J Clin Invest. 99:1997;894-900.
7. 107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation. Br J Pharmacol. 108:1993;1100-1106.
8. Masuda K., Kamimura T., Watanabe K., Suga T., Kanesaki M., Tekeuchi A., et al. Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro. Br J Pharmacol. 115:1995;883-888.
9. Mitsuhashi H., Asano S., Nonaka T., Hamamura I., Masuda K., Kiyoki M. Administration of truncated secretory leukoprotease inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters. Am J Respir Crit Care Med. 153:1997;369-374.
10. Schmitz M.L., dos Santos Silva M.A., Baeuerle P.A. Transactivation domain 2 (TA2) of p65 NF-κB. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J Biol Chem. 270:1995;15576-15584.
11. Wang D., Baldwin S.A. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem. 273:1998;29411-29416.
12. Goldring C.E., Reveneau S., Pinard D., Jeannin J-F. Hyporesponsiveness to lipopolysaccharide alters the composition of NF-κB binding to the regulatory regions of inducible nitric oxide synthase gene. Eur J Immunol. 28:1998;2960-2970.
13. d) mice respond bacterial lipopolysaccharide by activating NF-κB. J Leukoc Biol. 57:1995;174-179.
14. Poltorak A., He X., Smirnova I., Liu M-Y, Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr gene. Science. 282:1998;2085-2088.
15. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 162:1999;3749-3752.
16. Zhu J., Nathan C., Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. Biochim Biophys Acta. 1451:1999;219-223.
17. Medvedev A.E., Flo T., Ingalls R.R., Golenbock D.T., Teti G., Vogel S.N., et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-κB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol. 160:1998;4535-4542.
18. Schroder N.W.J., Opits B., Lamping N., Michelsen K.S., Zahringer U., Gobel U.B., et al. Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol. 165:2000;2683-2693.
19. Sano C., Shimizu T., Sato K., Kawauchi H., Tomioka H. Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-β), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol. 121:2000;77-85.
20. Vesteegen J.M.T., Logtenberg T., Ballieux R.E. Enumeration of IFN-γ producing human lymphocytes by spot-ELISA. J Immunol Methods. 111:1988;25-29.
21. Vincenti M.P., Burrell T.A., Taffet S.M. Regulation of NF-kappaB activity in murine macrophages: effect of bacterial lipopolysaccharide and phorbol ester. J Cell Physiol. 150:1992;204-213.
22. Buratoeski S., Chodosh L.A. Mobility shift DNA-binding assay using gel electrophoresis. Ausubel F.M., Brent R.E., Kingston R.E., Moore D., Seidman J.G., Smith J.A., Struhl K. Current protocols in molecular biology. vol. 2:1989;12.2.1-12.2.11 Wiley, New York.